Shanxi Zhendong Pharmaceutical Co.,Ltd

SZSE:300158 Stock Report

Market Cap: CN¥4.5b

Shanxi Zhendong PharmaceuticalLtd Balance Sheet Health

Financial Health criteria checks 6/6

Shanxi Zhendong PharmaceuticalLtd has a total shareholder equity of CN¥5.1B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥5.9B and CN¥801.7M respectively.

Key information

0%

Debt to equity ratio

CN¥0

Debt

Interest coverage ration/a
CashCN¥1.78b
EquityCN¥5.08b
Total liabilitiesCN¥801.65m
Total assetsCN¥5.88b

Recent financial health updates

Recent updates

Improved Revenues Required Before Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Stock's 39% Jump Looks Justified

Oct 22
Improved Revenues Required Before Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Stock's 39% Jump Looks Justified

We Think Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Can Afford To Drive Business Growth

Sep 30
We Think Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Can Afford To Drive Business Growth

Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Low P/S No Reason For Excitement

Aug 08
Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Low P/S No Reason For Excitement

Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Mar 07
Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Financial Position Analysis

Short Term Liabilities: 300158's short term assets (CN¥4.0B) exceed its short term liabilities (CN¥731.9M).

Long Term Liabilities: 300158's short term assets (CN¥4.0B) exceed its long term liabilities (CN¥69.8M).


Debt to Equity History and Analysis

Debt Level: 300158 is debt free.

Reducing Debt: 300158 has no debt compared to 5 years ago when its debt to equity ratio was 2.1%.

Debt Coverage: 300158 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 300158 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 19:33
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanxi Zhendong Pharmaceutical Co.,Ltd is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wenchao JiaoPing An Securities Co. Ltd.
Yin YePing An Securities Co. Ltd.
Wen Qing WeiShenwan Hongyuan Securities